-
Navigating Treatment Decisions In IgAN, With Jai Radhakrishnan, MD
10 Oct 2025 17:51 GMT
Once known as a poorly understood disease with few effective treatment options, IgA nephropathy (IgAN) is now at the center of a rapidly evolving therapeutic landscape. As the treatment armamentarium continues to expand, so too does the complexity of …
-
<![CDATA[Long-Term OS Data Guide Use of PARP Inhibitors in Ovarian Cancer]]>
09 Oct 2025 23:06 GMT
Preventing relapse of advanced ovarian cancer with PARP inhibitors is now an established strategy. As data from pivotal clinical trials have evolved, the stratification of patients by homologous recombination deficiency (HRD) and BRCA mutation status has …
-
New Guidelines and Novel Therapies in IgA Nephropathy, With Jai Radhakrishnan, MD
08 Oct 2025 20:09 GMT
Once known as a poorly understood disease with few effective treatment options, IgA nephropathy (IgAN) is now at the center of a rapidly evolving therapeutic landscape.
Advances in the understanding of its complex pathogenesis and the arrival of targeted …
-
United States Scleroderma Therapeutics Market Insights: Emerging Therapies and Key Growth Drivers 2025-2032
09 Oct 2025 13:40 GMT
… :
Boehringer Ingelheim International GmbH
Corbus Pharmaceuticals Holdings, Inc.
Bayer AG
Gilead … .
Pfizer, Inc.
Sanofi
GlaxoSmithKline plc
Cumberland Pharmaceuticals, Inc.
Actelion Pharmaceuticals, Inc.
Recent Developments …
-
Thyroid Eye Disease Treatment Market to Reach $4.23B by 2032 | Biologics & New Therapies Drive 5.92% CAGR
09 Oct 2025 11:58 GMT
… with Novartis, Sanofi, and GlaxoSmithKline driving innovation. Meanwhile, Asia … Pfizer (United States)
Regeneron Pharmaceuticals (United States)
Bristol-Myers … France)
AstraZeneca (United Kingdom)
GlaxoSmithKline (United Kingdom)
Swedish Orphan …
-
Mounjaro becomes India's second-highest selling drug: What's driving its rise?
08 Oct 2025 11:12 GMT
Within just six months of its launch, Eli Lilly's Mounjaro has shaken up India’s pharmaceutical landscape. The once-a-week injectable drug, prescribed for type 2 diabetes and weight management, has turned out to be India’s second-highest selling …
-
Comprehensive Report on the C-C Chemokine Receptor Type 4 Market: Opportunities and Challenges
09 Oct 2025 09:45 GMT
The Business Research Company's C-C Chemokine Receptor Type 4 Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034
LONDON, GREATER LONDON, UNITED KINGDOM, October 9, 2025 /EINPresswire.com/ -- What Is The Expected …
-
Atopic Dermatitis Cream Global Market Report 2025| Business Growth, Development Factors, Current and Trends till 2029
09 Oct 2025 09:30 GMT
…
• Sanofi S.A.
• AstraZeneca plc
• GlaxoSmithKline plc
• Eli Lilly and Company … Industries Ltd.
• Viatris Inc.
• Regeneron Pharmaceuticals, Inc.
What Are The Prominent …
-
Back Acne Treatment Market to Reach USD $2.76 Billion by 2029 at 8.9% CAGR
09 Oct 2025 09:30 GMT
The Business Research Company’s Back Acne Treatment Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034
LONDON, GREATER LONDON, UNITED KINGDOM, October 9, 2025 /EINPresswire.com/ -- How Big Is The Back Acne Treatment Market …
-
PM Internship Scheme 2025: List of companies where applicants can apply?
09 Oct 2025 07:04 GMT
… Enterprises Limited
106. Glenmark Pharmaceuticals Limited
107. Mahindra and … Agriscience Seeds Private Limited
275. GlaxoSmithKline Pharmaceuticals Limited
276. City Union … Sciences Limited
460. Suven Pharmaceuticals Limited
461. Societe Generale …
About
© 1995-2025